What were the key revenue drivers for Bristol Myers Squibb in the second quarter of 2025?

The 10-Q filing details the revenue performance across BMY's product portfolio. Investors should review the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section for a breakdown of revenue by product and therapeutic area, identifying which drugs contributed most significantly to top-line growth or experienced declines.

What is the company's current financial position and liquidity?

The Consolidated Balance Sheets provide a snapshot of BMY's financial health as of June 29, 2025, detailing assets, liabilities, and shareholders' equity. The Consolidated Statements of Cash Flows will further elaborate on the company's ability to generate cash from operations, invest in its business, and manage its financing activities, offering insights into its liquidity position.

Are there any significant legal or regulatory developments that investors should be aware of?

Item 1. Legal Proceedings and Item 1A. Risk Factors in Part II of the 10-Q address any ongoing or potential legal actions and significant risks the company faces. Investors should carefully review these sections for any material information that could impact the company's financial standing or future operations.

How are Bristol Myers Squibb's research and development efforts progressing?

While the 10-Q primarily focuses on financial results, updates on R&D investments and pipeline progress are often discussed within the 'Management's Discussion and Analysis' section. Investors should look for commentary on key clinical trial advancements, regulatory submissions, or new drug approvals that could influence future revenue streams.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2025

Summary

Bristol Myers Squibb (BMY) has filed its second quarter 2025 10-Q, providing investors with an update on its financial performance and operational developments. The report covers the period ending June 29, 2025, and highlights the company's ongoing focus on strategic growth initiatives and product portfolio management. Investors should pay close attention to the company's revenue trends, research and development investments, and any updates on key litigation or regulatory matters that could impact future performance.

Financial Highlights

55 data points

Beta

Revenue

$12.27B

0.7% Gross Margin

Net Income

$1.31B

0.1% Net Margin

EPS (Diluted)

$0.64

Total Assets

$94.68B

Cash & Equivalents

$12.60B

Free Cash Flow

$3.56B

Financial Statements

Beta

Revenue	$12.27B
Cost of Revenue	$3.37B
Gross Profit	$8.90B
R&D Expenses	$2.58B
SG&A Expenses	$1.71B
Operating Expenses	$10.50B
Net Income	$1.31B
EPS (Basic)	$0.64
EPS (Diluted)	$0.64
Shares Outstanding (Basic)	2.04B
Shares Outstanding (Diluted)	2.04B

Key Highlights

1The report details the company's financial performance for the second quarter of 2025, with specific focus on revenue generation and profitability.
2Key updates on the company's product pipeline and R&D investments are provided, indicating continued commitment to innovation.
3Management's Discussion and Analysis section offers insights into the operational drivers and strategic decisions impacting the company's financial results.
4Information regarding legal proceedings and risk factors is presented, which could pose potential challenges or opportunities for BMY.
5The filing includes the consolidated financial statements, offering a comprehensive view of the company's assets, liabilities, and equity as of the reporting period.
6Consolidated statements of cash flows will provide investors with clarity on the company's cash generation and utilization activities during the quarter.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions